NTLA vs PACB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PACB Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pacific Biosciences of California, Inc. (PACB) driven by superior Growth & Margin, Momentum & Technical while NTLA counters with relative strength in Options & Structure. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NTLA Revenue | PACB Revenue | NTLA Op. Margin | PACB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $80M | -298.6% | -128.4% | PACB |
| FY2019 | $40M | $90M | -246.8% | -110.6% | PACB |
| FY2020 | $60M | $80M | -235.5% | -132.3% | PACB |
| FY2021 | $30M | $130M | -810.4% | -161.2% | PACB |
| FY2022 | $50M | $130M | -879.0% | -239.4% | PACB |
| FY2023 | $40M | $200M | -1420.5% | -166.8% | PACB |
| FY2024 | $60M | $150M | -923.1% | -308.0% | PACB |
| FY2025 | $70M | $160M | -651.7% | -346.2% | PACB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NTLA | PACB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $615.1M | Larger Scale | NTLA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -48.0% | +5.5% | Higher Growth | PACB |
| Operating Margin (TTM) Profitability | -826.0% | -333.0% | Higher Margin | PACB |
| Net Profit Margin Profitability | 0.0% | -81.3% | Higher Margin | NTLA |
| Return on Equity (ROE) Capital Efficiency | -62.6% | -929.3% | Higher ROE | NTLA |
| 52-Week Range Position Momentum | 20% ($8โ$18) | 34% ($1โ$3) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 2.30ฮฒ ยท 87% Vol | 2.27ฮฒ ยท 112% Vol | Lower Realized Risk | NTLA |
| Unified Institutional Score Composite Signal | 49.9 / 100 (HOLD) | 38.0 / 100 (SELL) | Higher Composite | NTLA |